Impact of Cardiometabolic Risk Factor Burden and Therapeutic Control on the Prognosis of Alcohol-Related Hepatitis: A Biopsy-Proven Cohort Study With External Multicentre Validation.
Cardiometabolic risk factors (CMRF) have traditionally been overlooked in alcohol-related liver disease (ALD) and their prognostic impact in alcohol-related hepatitis (AH) remains poorly defined. We evaluated the influence of CMRF burden and therapeutic control on complications and mortality in AH.
We prospectively enrolled 100 patients with biopsy-proven AH. CMRF (obesity, hypertension, diabetes, hyper-triglyceridaemia, low HDL cholesterol) and therapeutic control prior to admission were assessed. A cardiometabolic burden (CMB) score (0-10), incorporating CMRF number and control, was constructed. External validity was tested in an independent multicentre cohort of 332 patients with clinically diagnosed AH.
In the primary cohort, patients with CMRF had higher 1-year mortality than those without (48% vs. 25%, p = 0.030) and more frequent in-hospital complications. Clustered CMRF (≥ 3) independently predicted 1-year mortality after adjustment for MELD, age and sex (HR = 4.1, 95% CI: 1.66-10, p = 0.002). Increasing CMB scores (≥ 5) similarly associated with higher mortality (HR = 4.4, 95% CI: 1.76-11, p = 0.002). These findings were reproduced in the external cohort, where ≥ 3 CMRF predicted 1-year mortality (HR = 3.0, 95% CI: 1.97-4.7, p < 0.001). Furthermore, ≥ 3 CMRF independently predicted 1-year mortality beyond MELD and Lille response in treated patients (HR = 2.6, 95% CI: 1.46-4.5, p = 0.001).
Clustered (≥ 3) and poorly controlled CMRF significantly impair survival and increase complication rates in AH. These findings, confirmed in an independent multicentre cohort, support integrating systematic cardiometabolic evaluation into routine clinical ALD management.
We prospectively enrolled 100 patients with biopsy-proven AH. CMRF (obesity, hypertension, diabetes, hyper-triglyceridaemia, low HDL cholesterol) and therapeutic control prior to admission were assessed. A cardiometabolic burden (CMB) score (0-10), incorporating CMRF number and control, was constructed. External validity was tested in an independent multicentre cohort of 332 patients with clinically diagnosed AH.
In the primary cohort, patients with CMRF had higher 1-year mortality than those without (48% vs. 25%, p = 0.030) and more frequent in-hospital complications. Clustered CMRF (≥ 3) independently predicted 1-year mortality after adjustment for MELD, age and sex (HR = 4.1, 95% CI: 1.66-10, p = 0.002). Increasing CMB scores (≥ 5) similarly associated with higher mortality (HR = 4.4, 95% CI: 1.76-11, p = 0.002). These findings were reproduced in the external cohort, where ≥ 3 CMRF predicted 1-year mortality (HR = 3.0, 95% CI: 1.97-4.7, p < 0.001). Furthermore, ≥ 3 CMRF independently predicted 1-year mortality beyond MELD and Lille response in treated patients (HR = 2.6, 95% CI: 1.46-4.5, p = 0.001).
Clustered (≥ 3) and poorly controlled CMRF significantly impair survival and increase complication rates in AH. These findings, confirmed in an independent multicentre cohort, support integrating systematic cardiometabolic evaluation into routine clinical ALD management.
Authors
SolĂs-Muñoz SolĂs-Muñoz, de la Flor-Robledo de la Flor-Robledo, Rivas-Izquierdo Rivas-Izquierdo, DomĂnguez-Humanes DomĂnguez-Humanes, Casiano-Manzano Casiano-Manzano, NoguĂ©s-Grajera NoguĂ©s-Grajera, Fernández-Bermejo Fernández-Bermejo, JimĂ©nez-Colmenarez JimĂ©nez-Colmenarez, Ledo-Mendoza Ledo-Mendoza, MartĂn-Holgado MartĂn-Holgado, Monge-Romero Monge-Romero, GarcĂa-Martos GarcĂa-Martos, GarcĂa-AbadĂa GarcĂa-AbadĂa, GarcĂa-MonzĂłn GarcĂa-MonzĂłn, SolĂs-Herruzo SolĂs-Herruzo
View on Pubmed